Should employers continue covering GLP-1 weight-loss medications when healthcare budgets are already under pressure?

This question is becoming increasingly difficult for HR leaders to answer.

For employees managing obesity and related medical conditions, treatments such as Wegovy and Zepbound may represent an important healthcare option. For employers, however, expanded access can introduce substantial prescription drug spending, particularly when treatment continues over an extended period.

The challenge extends beyond deciding whether a medication belongs in a health plan. HR departments must also consider fairness, financial sustainability, employee expectations, and the consequences of changing an existing benefit.

As organizations prepare their 2027 benefits strategies, GLP-1 coverage is becoming a test of how effectively HR can balance business priorities with employee healthcare needs.

Why GLP-1 Coverage Is Becoming a Difficult Employer Decision

The GLP-1 conversation has changed significantly.

A few years ago, these medications were primarily discussed in relation to diabetes treatment. Today, demand for medications approved for chronic weight management has created a broader benefits debate.

Employers are facing two competing pressures.

On one side, employees increasingly expect health insurance to provide access to treatments that may improve their health. On the other, organizations must manage rising medical expenses without significantly increasing premiums, deductibles, or other employee costs.

Recent research illustrates the tension.

According to the 2026 KFF Employer Health Benefits Survey, 18% of employers with 200 or more workers covered GLP-1 medications primarily for weight loss. Among employers with at least 5,000 workers, that figure reached 33%.

The spending impact was equally important. Among the largest employers offering this coverage, 61% reported that GLP-1 medications had a significant effect on their prescription drug spending.

Coverage decisions are also moving in the opposite direction at some organizations.

The same survey found that 12% of employers with 200 or more workers that did not currently cover GLP-1s for weight loss had discontinued that coverage during the previous 12 months.

This suggests that offering GLP-1 benefits is no longer simply a question of expanding employee healthcare options. It is becoming an ongoing financial and workforce-management decision.

The Real Cost Problem Is Bigger Than the Price of a Prescription

When evaluating GLP-1 benefits, employers often begin with medication prices.

However, the financial consequences are more complicated.

Consider a company that introduces weight-management medication coverage during open enrollment.

Initially, only a small number of employees may use the benefit. Over time, additional employees may qualify, dependents may begin treatment, and existing users may continue taking medication.

Even if negotiated drug prices decline, overall spending can increase when utilization rises.

This creates a different financial challenge from a benefit involving a predictable, one-time expense.

What employers need to calculate

An effective GLP-1 financial assessment should consider several factors:

Cost consideration	Why it matters
Eligible plan members	Establishes how many employees and dependents could qualify
Expected enrollment	Helps estimate how many members may begin treatment
Net medication cost	Reflects actual plan spending after applicable discounts and rebates
Treatment duration	Accounts for members who may remain on medication for extended periods
Associated services	Includes any additional clinical consultations, monitoring, or support
Future utilization	Helps predict how spending could change as demand and treatment options evolve

HR should also understand how its health plan is funded.

A self-funded employer generally bears covered claims costs directly, subject to its funding arrangements. A fully insured employer may experience the impact through insurance premiums and renewal negotiations.

The financial risk therefore differs even when two employers offer similar coverage.

The important distinction: A lower medication price does not necessarily mean a lower total benefits bill.

Three GLP-1 Coverage Models Employers Can Consider

There is no single benefits design that works for every organization.

Workforce demographics, financial resources, existing prescription benefits, and healthcare priorities all influence the appropriate coverage approach.

Instead of viewing GLP-1 benefits as a simple yes-or-no decision, employers can evaluate different plan structures.

Model A: Coverage limited to selected medical indications

Under this approach, employers retain coverage for specified medical conditions, such as type 2 diabetes, while excluding prescriptions primarily intended for weight management.

This model can provide greater budget predictability, although employees seeking treatment for obesity may face substantial out-of-pocket costs.

Coverage rules should distinguish clearly between medications and their approved indications, since some GLP-1-related treatments have multiple FDA-approved uses.

Model B: Weight-management coverage with clinical eligibility requirements

Here, employers extend coverage to eligible members while applying evidence-based clinical criteria.

An independent clinical team or plan administrator may evaluate medical necessity, approved indications, and other relevant requirements.

This model provides access to a broader group of employees while introducing controls intended to manage inappropriate utilization.

However, complicated approval procedures can delay treatment and undermine employee confidence.

Model C: Broader coverage with integrated clinical support

A more comprehensive model combines medication coverage with access to appropriate clinical services, such as nutrition support and ongoing medical monitoring.

The objective is to support patients throughout treatment rather than treating prescription coverage as a standalone benefit.

This option may provide a more coordinated experience, although it introduces additional costs and vendor-management responsibilities.

Employers should evaluate these models against projected spending, clinical appropriateness, administrative complexity, and employee access before choosing a plan.

Why Cutting GLP-1 Coverage Can Create an Employee Relations Problem

Removing an expensive benefit may appear to be an effective way to reduce health plan spending.

But the financial analysis does not capture every consequence.

Imagine an employee who has been receiving a prescribed GLP-1 medication through the company’s health insurance plan.

The employer announces that weight-management coverage will end at the next renewal.

The employee now faces uncertainty about treatment continuity, future prescription expenses, and available alternatives.

Although an employer may have legitimate financial reasons for changing benefits, a sudden coverage change can create frustration and distrust.

This is particularly relevant when employees believe the organization previously encouraged them to take advantage of comprehensive healthcare benefits.

HR should evaluate the transition, not just the savings

Before modifying GLP-1 benefits, employers should consider whether existing members will receive advance notice, whether transitional arrangements are appropriate, and how employees can seek coverage reviews or exceptions.

Communication must also distinguish between changing insurance coverage and advising someone to stop treatment. Clinical treatment decisions belong to patients and their healthcare professionals.

Employers should avoid messaging that stigmatizes obesity or implies that medication use reflects an employee’s personal choices or work performance.

A carefully managed benefits transition can help preserve employee trust even when cost-related changes are unavoidable.

The Pharmacy Contract May Offer More Flexibility Than Expected

Organizations sometimes assume that reducing GLP-1 spending requires restricting employee access.

That is not necessarily the only option.

Pharmacy benefit manager contracts, formulary arrangements, and purchasing strategies can affect how much the employer ultimately pays.

For example, one PBM may offer a substantial manufacturer rebate, while another may provide a lower initial price with a different fee structure.

The more attractive rebate arrangement is not automatically the less expensive option.

Employers need visibility into the final net cost rather than relying exclusively on advertised discounts.

This is becoming more important as the market evolves.

According to Mercer’s 2026 employer benefits findings, 41% of large employers were evaluating different contracting models offered by major PBMs, while 37% were examining newer PBM alternatives.

For HR leaders, this creates an opportunity to make pharmacy procurement part of broader benefits planning.

Before approving a renewal, employers should request a comparison that reflects medication costs, rebates, administrative charges, and projected utilization under each proposed arrangement.

Independent benefits consultants can also help examine whether the pricing assumptions are realistic.

Are Direct-to-Consumer GLP-1 Programs Worth Considering?

Another development is the growing availability of manufacturer-direct purchasing and telehealth programs.

These options may allow eligible individuals to access medications outside traditional pharmacy benefit arrangements.

Their appeal is understandable: some programs advertise cash prices that appear lower than conventional list prices.

However, there are important questions for HR to resolve before recommending or financially supporting such arrangements.

A vendor should be able to explain how prescriptions are issued, whether medications are FDA-approved, how patients are monitored, and how personal health information is protected.

Employers should also understand whether advertised prices include required consultations, subscription fees, or other services.

The FDA has specifically warned about unapproved GLP-1 products, including risks associated with improperly marketed compounded medications.

An employer-sponsored reimbursement arrangement may also introduce legal, tax, and plan-compliance considerations.

For these reasons, alternative purchasing programs should undergo the same financial, clinical, and legal review as other healthcare benefits.

The Overlooked Issue: Fairness Across the Workforce

GLP-1 coverage decisions may affect employees differently.

A worker with a higher salary may be able to purchase medication without insurance assistance, while someone with less disposable income may have no realistic alternative if coverage is unavailable.

The same concern applies when plans impose substantial coinsurance or cost-sharing requirements.

A technically available benefit may still be financially inaccessible.

HR professionals should examine whether coverage rules create unintended access barriers for lower-paid employees or people with complex medical needs.

They should also review whether additional participation requirements are practical for workers with different schedules and caregiving responsibilities.

For example, requiring employees to attend frequent daytime coaching sessions could be difficult for shift workers unless alternative arrangements are available.

Where a program qualifies as a health-contingent wellness program, applicable nondiscrimination and reasonable-alternative requirements must also be considered.

The U.S. Department of Labor’s August 2026 guidance reinforces important requirements governing such programs.

Fairness does not necessarily mean identical treatment for everyone. It means establishing appropriate, consistently administered policies that account for different medical circumstances and applicable legal protections.

What a Practical 2027 GLP-1 Benefits Review Should Look Like

Rather than reacting to an unexpected increase in pharmacy spending, HR can incorporate GLP-1 coverage into its annual benefits governance process.

A structured review can be organized into three stages.

Stage 1: Establish the current position

Begin by collecting existing plan information.

Review spending trends, current coverage provisions, administrative requirements, and utilization data available from the insurer or PBM.

At this stage, employers should also identify whether prescription spending relates to diabetes, weight management, or other covered medical indications, where reliable aggregated reporting permits.

HR should not request individual employee diagnoses or identifiable treatment histories for routine benefits planning.

The goal is to establish an accurate financial and operational baseline.

Stage 2: Test the available options

Next, assess the consequences of maintaining, expanding, or modifying coverage.

The review should consider projected costs, employee financial exposure, access restrictions, legal obligations, and implementation requirements.

This is also the appropriate time to question vendors about net pricing and administrative fees.

Decisions should not depend solely on projected drug savings. Employers should consider how changes could affect healthcare access and employees who are already receiving treatment.

Stage 3: Approve, communicate, and monitor

Once leadership has selected a benefits approach, HR should coordinate its implementation with the plan administrator.

Employees need accurate information before coverage changes take effect.

The organization should also establish a routine reporting process to determine whether actual spending and utilization match the original assumptions.

A sample HR benefits review dashboard

Performance indicator	Question HR should answer
GLP-1 spending trend	Is total plan spending increasing or decreasing?
Average net cost per prescription	Are negotiated prices improving?
Covered utilization	How is medication use changing across approved indications?
Prior authorization outcomes	Are eligible members experiencing avoidable access difficulties?
Employee cost-sharing	Can covered employees reasonably afford treatment?
Program operating costs	Are additional vendor services delivering measurable value?
Benefits inquiries and complaints	Do employees understand the coverage policy?

These indicators should be monitored at an appropriately aggregated level, with privacy safeguards and a recognition that financial and clinical outcomes may take different amounts of time to emerge.

What HR Leaders Should Avoid

Cost-management initiatives can become counterproductive when they are introduced without sufficient planning.

One common problem is adding multiple vendors without understanding which services are already available through the insurer or existing wellness programs.

Another is making major policy changes based on a single quarter of unusually high prescription spending.

Employers may also overestimate short-term savings from improved employee health. GLP-1 medications can offer clinically meaningful benefits for eligible patients, but those benefits do not automatically translate into immediate reductions in employer medical claims.

Finally, HR should avoid turning medication eligibility decisions into workplace management decisions.

A manager should not be expected to determine whether an employee needs weight-management treatment. Such assessments should remain within the appropriate clinical and health plan processes.

The HR function is to establish responsible benefits policies, protect employee interests, and oversee program administration—not to make individual medical decisions.

What Happens Next? GLP-1 Benefits Beyond 2026

The GLP-1 market is continuing to change.

Additional treatment options, including oral medications, may influence prescribing patterns, employee preferences, and pricing arrangements.

At the same time, employers face broader healthcare cost pressures.

The challenge for 2027 will be determining whether new purchasing opportunities and more sophisticated plan designs can improve affordability without creating unnecessary barriers to care.

HR teams should remain prepared to revisit their approach as new clinical evidence, drug approvals, and pricing information become available.

Organizations that build flexibility into their benefits strategy may be better positioned to respond than those that make rigid, long-term decisions based on current prices alone.

Final Perspective: The Best GLP-1 Strategy Is Not Necessarily the Cheapest

An effective employee benefits program needs to be financially sustainable. But sustainability involves more than reducing prescription spending.

It also requires predictable administration, clear employee communication, appropriate healthcare access, and confidence that coverage decisions are being made responsibly.

For HR professionals, GLP-1 medications present an opportunity to strengthen the way organizations evaluate healthcare benefits.

The priority should be to understand what the plan is paying for, assess whether available services are appropriate and cost-effective, and make changes with careful consideration of employees already relying on coverage.

The most successful employers will not necessarily be those offering the broadest or most restrictive GLP-1 benefits. They will be those able to explain why their coverage approach is financially responsible, clinically appropriate, and fair to their workforce.

Common Questions for HR Benefits Leaders

1. Should GLP-1 coverage be part of the annual open enrollment review?

Yes. Employers should review medication coverage, cost-sharing provisions, administrative requirements, and changes to approved treatments during annual benefits planning. Material changes should be communicated before the relevant coverage period begins.

2. Can smaller employers offer GLP-1 benefits without significantly increasing premiums?

It depends on the insurer’s pricing, the plan’s existing prescription coverage, anticipated utilization, and other factors. Smaller employers may have less flexibility over pharmacy contracts than large self-funded organizations. Comparing available plan options can help clarify the financial implications.

3. What should HR ask a PBM before renewing its contract?

Employers should seek clear explanations of net medication costs, rebates, formulary placement, administrative fees, utilization controls, and reporting capabilities. Contract comparisons should reflect expected total spending rather than focusing on a single discount.

4. Is GLP-1 coverage an employee retention benefit?

Comprehensive healthcare benefits can influence employee satisfaction and perceptions of an employer. However, HR should not assume that GLP-1 coverage independently improves retention without supporting workforce data.

5. How should employers handle employees already receiving treatment when coverage changes?

Employers should provide appropriate advance notice, explain the effective date and coverage rules, and ensure employees understand review and appeal options. HR should coordinate with the health plan and appropriate advisers regarding any required transition arrangements.